CN Patent

CN102770129A — 治疗癌症的方法和组合物

Assigned to Ariad Gene Therapeutics Inc · Expires 2012-11-07 · 14y expired

What this patent protects

本发明涉及使用3-(咪唑并[1，2-b]哒嗪-3-基乙炔基)-4-甲基-N-(4-((4-甲基哌嗪-1-基)-甲基)-3-(三氟甲基)苯基)苯甲酰胺治疗癌症的方法、试剂盒以及药物组合物。

USPTO Abstract

本发明涉及使用3-(咪唑并[1，2-b]哒嗪-3-基乙炔基)-4-甲基-N-(4-((4-甲基哌嗪-1-基)-甲基)-3-(三氟甲基)苯基)苯甲酰胺治疗癌症的方法、试剂盒以及药物组合物。

Drugs covered by this patent

ponatinib-hydrochloride (PONATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN102770129A
Jurisdiction: CN
Classification: —
Expires: 2012-11-07
Drug substance claim: No
Drug product claim: No
Assignee: Ariad Gene Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.